Strategies to prevent persistent or relapsed mixed cryoglobulinemia - Sorbonne Université
Article Dans Une Revue Expert Opinion on Orphan Drugs Année : 2020

Strategies to prevent persistent or relapsed mixed cryoglobulinemia

Résumé

Mixed cryoglobulinemia (MC) are immune complexes that can deposit in small and medium size arteries and cause systemic vasculitis called cryoglobulinemic vasculitis (CryoVas). CryoVas most common clinical manifestations include purpura, arthralgia and/or arthritis, skin ulcers, peripheral neuropathy, nephritis, and may progress to more life-threatening illness. Hepatitis C virus (HCV) infection is the more frequent condition to be assessed in patients with MC, followed by connective tissue diseases and B-cell non-Hodgkin’s lymphoma. In HCV-related cases, the mainstay of CryoVas treatment is interferon free antiviral therapy. However, a significant proportion of patients who show HCV eradication will develop persistent CryoVas needing treatment intensification.
Fichier principal
Vignette du fichier
Boleto et al. - 2020 - Strategies to prevent persistent or relapsed mixed.pdf (251.51 Ko) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02998024 , version 1 (10-11-2020)

Identifiants

Citer

Gonçalo Boleto, David Saadoun, Patrice Cacoub. Strategies to prevent persistent or relapsed mixed cryoglobulinemia. Expert Opinion on Orphan Drugs, 2020, 8 (5), pp.137-143. ⟨10.1080/21678707.2020.1767586⟩. ⟨hal-02998024⟩
46 Consultations
195 Téléchargements

Altmetric

Partager

More